IJRR

International Journal of Research and Review

| Home | Current Issue | Archive | Instructions to Authors | Journals |

Research Article

Year: 2023 | Month: August | Volume: 10 | Issue: 8 | Pages: 1100-1109

DOI: https://doi.org/10.52403/ijrr.202308138

Optimizing Real-World Evidence Framework for Oncology: Challenges, Opportunities, and Way Forward for India

Dr. Ankita Jain1, Dr. Manmohan Singh2, Dr. Sonali Dighe3, Dr. Ishan Patel4

1Medical Affairs, Oncology, Pfizer Biopharmaceutical Group, Emerging Market, India
2Regional Oncology Medical Lead, Pfizer Biopharmaceutical Group, Emerging Market, Hongkong
3Sr. Director, Medical Affairs, Pfizer Biopharmaceutical Group, Emerging Market, India
4Senior Manager Medical Affairs, Oncology Pfizer Biopharmaceutical Group, Emerging Market, India

Corresponding Author: Dr. Ishan Patel

ABSTRACT

Given the increasing prevalence of rare and metastatic cancers, the utilization of real-world evidence (RWE) has become imperative. RWE plays a crucial role in generating oncology data that aids healthcare providers in their routine clinical practice and, more importantly, informs policymaking decisions. Pfizer and IQVIA joined forces to convene a ground breaking round table discussion involving stakeholders from both private and public organizations. The primary objective of this collaborative initiative was to explore the current state of the real-world evidence (RWE) framework in India, particularly within the realm of oncology. By assessing recent changes in the healthcare landscape, the discussion aimed to identify opportunities for government initiatives, acknowledge associated challenges, and chart a path forward for optimizing oncology clinical decision-making.
Several key outcomes emerged from this pioneering endeavour. Firstly, there was a strong emphasis on the significance of public-private partnerships in generating real-world data (RWD) within the Indian context. Specifically, the integration of electronic health records (EHRs) and cancer registries was highlighted as crucial for enhancing the quality and accessibility of RWD. Secondly, the discussion underscored the importance of harnessing real-world claims data obtained from both private and government insurance schemes to advance health outcome research. This data source holds immense potential for informing evidence-based decision-making in the field of oncology. Additionally, the round table meeting facilitated the generation of longitudinal RWD through government-led initiatives, opening avenues for comprehensive and long-term data analysis. Lastly, the exploration of utilizing RWE in reimbursement decisions and potential expansion of indications emerged as a significant area of focus.
The insights and conclusions derived from this round table meeting serve as a foundation for continued discussions. The diverse and extensive collection of RWD pertaining to oncology therapeutics holds immense potential to guide decision-making not only within India but also across other Asia-Pacific countries

Keywords: Real-world evidence, policymaking, oncology

[PDF Full Text]